32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One

[1]  J. Limacher,et al.  Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC , 2017, Journal of Immunotherapy for Cancer.

[2]  R. Kiessling,et al.  Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma , 2017, Journal of Immunotherapy for Cancer.

[3]  J. Berlin,et al.  Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. , 2017 .

[4]  S. Jagannath,et al.  First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. , 2017 .

[5]  B. Lei,et al.  Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. , 2017 .

[6]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[7]  Arnone Nithichanon,et al.  A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines , 2017, Scientific Reports.

[8]  D. Uecker,et al.  Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death , 2017, Journal of Immunotherapy for Cancer.

[9]  Adam A. Margolin,et al.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.

[10]  E. Kleinerman,et al.  Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases , 2017, Cancer Immunology Research.

[11]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[12]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Sean C. Bendall,et al.  Systemic Immunity Is Required for Effective Cancer Immunotherapy , 2017, Cell.

[14]  David M. Schauder,et al.  Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors , 2017, Proceedings of the National Academy of Sciences.

[15]  Todd M. Allen,et al.  The epigenetic landscape of T cell exhaustion , 2016, Science.

[16]  Russell M Gordley,et al.  Engineering dynamical control of cell fate switching using synthetic phospho-regulons , 2016, Proceedings of the National Academy of Sciences.

[17]  Shulin Li,et al.  Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism , 2016, Oncoimmunology.

[18]  Pornpimol Charoentong,et al.  Computational genomics tools for dissecting tumour–immune cell interactions , 2016, Nature Reviews Genetics.

[19]  Douglas B. Johnson,et al.  Systems immune monitoring in cancer therapy. , 2016, European journal of cancer.

[20]  Ton N. Schumacher,et al.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.

[21]  Daniel Abate-Daga,et al.  CAR models: next-generation CAR modifications for enhanced T-cell function , 2016, Molecular therapy oncolytics.

[22]  F. Hodi,et al.  Talimogene Laherparepvec for the Treatment of Advanced Melanoma , 2016, Clinical Cancer Research.

[23]  Xiaoxiao Wang,et al.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. , 2016, Cancer cell.

[24]  T. Ideker,et al.  Translation of Genotype to Phenotype by a Hierarchy of Cell Subsystems , 2016, Cell systems.

[25]  E. Felip,et al.  TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. , 2016, The Lancet. Oncology.

[26]  M. Sade-Feldman,et al.  Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in Stage-IV melanoma patients treated with ipilimumab , 2016 .

[27]  R. Halaban,et al.  Pre-treatment patient selection for nivolumab benefit based on serum mass spectra , 2015, Journal of Immunotherapy for Cancer.

[28]  S. Forman,et al.  Smart CARs engineered for cancer immunotherapy , 2015, Current opinion in oncology.

[29]  B. Johnston,et al.  Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies , 2015, Oncotarget.

[30]  R. Ferris.  Immunology and Immunotherapy of Head and Neck Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Leonard Moise,et al.  iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines , 2015, Human vaccines & immunotherapeutics.

[32]  Kirsten E Diggins,et al.  Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data. , 2015, Methods.

[33]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[34]  David C. Smith,et al.  Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[36]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[38]  B. Coventry,et al.  Cancer Management and Research Dovepress Long-term Survival in Advanced Melanoma Patients Using Repeated Therapies: Successive Immunomodulation Improving the Odds? , 2022 .

[39]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[41]  Eugene S. Kim,et al.  Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes , 2015, Nature Medicine.

[42]  R. Ferris,et al.  PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. , 2015, Cancer research.

[43]  B. Jessen,et al.  Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model , 2014, Cancer Immunology Research.

[44]  L. Moretta,et al.  Effect of tumor cells and tumor microenvironment on NK‐cell function , 2014, European journal of immunology.

[45]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[47]  J. Hubbell,et al.  Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. , 2014, Biomaterials.

[48]  Enrico Proietti,et al.  Exploiting dendritic cells in the development of cancer vaccines , 2013, Expert review of vaccines.

[49]  G. Coukos,et al.  CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor , 2013, Clinical Cancer Research.

[50]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[51]  L. Southerland,et al.  VIPhyb, an Antagonist of Vasoactive Intestinal Peptide Receptor, Enhances Cellular Antiviral Immunity in Murine Cytomegalovirus Infected Mice , 2013, PloS one.

[52]  T. So,et al.  Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family Molecules , 2013, Front. Immunol..

[53]  M. Chiriva-Internati,et al.  Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen , 2013, Cancer Immunology, Immunotherapy.

[54]  T. Ideker,et al.  A gene ontology inferred from molecular networks , 2012, Nature Biotechnology.

[55]  Marianna Sabatino,et al.  Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment , 2012, Journal of immunotherapy.

[56]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[57]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[58]  L. Butterfield,et al.  A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma , 2012, Cancer Immunology, Immunotherapy.

[59]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[60]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[61]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[62]  Russell G. Jones,et al.  Enhancing CD8 T-cell memory by modulating fatty acid metabolism , 2009, Nature.

[63]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[64]  Eva Mezey,et al.  Simultaneous Visualization of Multiple Antigens with Tyramide Signal Amplification using Antibodies from the same Species , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[65]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[66]  J. Schlesselman,et al.  Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Mann,et al.  Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). , 2003, Journal of proteome research.